| Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial WP Fendler, J Calais, M Eiber, RR Flavell, A Mishoe, FY Feng, ... JAMA oncology 5 (6), 856-863, 2019 | 683 | 2019 |
| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 252 | 2019 |
| Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer WP Fendler, S Reinhardt, H Ilhan, A Delker, G Böning, FJ Gildehaus, ... Oncotarget 8 (2), 3581, 2016 | 233 | 2016 |
| Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake K Seystahl, V Stoecklein, U Schüller, E Rushing, G Nicolas, N Schäfer, ... Neuro-oncology 18 (11), 1538-1547, 2016 | 138 | 2016 |
| Recent advances of PET imaging in clinical radiation oncology M Unterrainer, C Eze, H Ilhan, S Marschner, O Roengvoraphoj, ... Radiation Oncology 15, 1-15, 2020 | 136 | 2020 |
| First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients MJ Zacherl, FJ Gildehaus, L Mittlmeier, G Böning, A Gosewisch, V Wenter, ... Journal of Nuclear Medicine 62 (5), 669-674, 2021 | 134 | 2021 |
| Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer WP Fendler, DBP Tiega, H Ilhan, PM Paprottka, V Heinemann, TF Jakobs, ... Journal of Nuclear Medicine 54 (8), 1202-1208, 2013 | 114 | 2013 |
| Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH … H Ahmadzadehfar, K Rahbar, RP Baum, R Seifert, K Kessel, ... European Journal of Nuclear Medicine and Molecular Imaging 48, 113-122, 2021 | 104 | 2021 |
| Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors H Ilhan, A Goritschan, P Paprottka, TF Jakobs, WP Fendler, A Todica, ... Journal of Nuclear Medicine 56 (11), 1654-1660, 2015 | 101 | 2015 |
| Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors H Ilhan, S Lindner, A Todica, CC Cyran, R Tiling, CJ Auernhammer, ... European journal of nuclear medicine and molecular imaging 47, 870-880, 2020 | 100 | 2020 |
| Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy RA Werner, H Ilhan, S Lehner, L Papp, N Zsótér, I Schatka, DO Muegge, ... Molecular imaging and biology 21, 582-590, 2019 | 90 | 2019 |
| Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival S Rudisile, A Gosewisch, V Wenter, M Unterrainer, G Böning, ... BMC cancer 19, 1-9, 2019 | 88 | 2019 |
| Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity RA Werner, C Lapa, H Ilhan, T Higuchi, AK Buck, S Lehner, P Bartenstein, ... Oncotarget 8 (4), 7039, 2016 | 85 | 2016 |
| Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies CJ Auernhammer, C Spitzweg, MK Angele, S Boeck, A Grossman, ... The lancet Diabetes & endocrinology 6 (5), 404-415, 2018 | 80 | 2018 |
| Outcome after PSMA PET/CT–based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a 2-institution retrospective analysis NS Schmidt-Hegemann, C Stief, TH Kim, C Eze, S Kirste, I Strouthos, M Li, ... Journal of Nuclear Medicine 60 (2), 227-233, 2019 | 78 | 2019 |
| Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy NS Schmidt-Hegemann, WP Fendler, H Ilhan, A Herlemann, A Buchner, ... Radiation Oncology 13, 1-9, 2018 | 67 | 2018 |
| Impact of 68Ga-DOTATATE PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum H Ilhan, WP Fendler, CC Cyran, C Spitzweg, CJ Auernhammer, ... Annals of surgical oncology 22, 164-171, 2015 | 63 | 2015 |
| Impact of 68Ga-PSMA PET/CT on the radiotherapeutic approach to prostate cancer in comparison to CT: a retrospective analysis NS Schmidt-Hegemann, C Eze, M Li, P Rogowski, C Schaefer, C Stief, ... Journal of Nuclear Medicine 60 (7), 963-970, 2019 | 61 | 2019 |
| Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer Y Du, I Carrio, G De Vincentis, S Fanti, H Ilhan, C Mommsen, E Nitzsche, ... European journal of nuclear medicine and molecular imaging 44, 1671-1678, 2017 | 60 | 2017 |
| Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference C Zamboglou, TF Fassbender, L Steffan, F Schiller, T Fechter, M Carles, ... Radiotherapy and Oncology 141, 208-213, 2019 | 56 | 2019 |
